Duodenal cancer

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
Wednesday, April 10, 2024
Hypertelorism, DLT, Safety, Radiation, Pancreatic cancer, TSX, PR, Cancer, LFT, Regulatory T cell, Patient, MDNA, RDE, Duodenal cancer, Toxicity, Melanoma, BCC, MCC, AACR, VLS, MSI-H, PD, NK, Combination therapy, Pharmaceutical industry

March 22, 2024) include:

Key Points: 
  • March 22, 2024) include:
    Acceptable safety profile: No dose limiting toxicity (DLT) reported and no evidence of vascular leak syndrome (VLS).
  • A new lymph node lesion developed during a 8-week MDNA11 treatment break (vacation) was treated with a single course of radiotherapy prior to resumption of MDNA11.
  • A new lymph node lesion developed at week 16 while baseline target and non-target lesions remained stable or decreased.
  • Monotherapy expansion is continuing to enroll patients with metastatic melanoma, non-melanoma skin cancers (cSCC, MCC, and BCC) and MSI-H/dMMR tumors.

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
Tuesday, April 9, 2024
Toxicity, PR, Combination therapy, VLS, MSI-H, PD, LFT, RDE, Duodenal cancer, Patient, Hypertelorism, Radiation, MCC, MDNA, AACR, TSX, DLT, Pancreatic cancer, Safety, Regulatory T cell, Melanoma, Cancer, BCC, NK, Pharmaceutical industry

March 22, 2024) include:

Key Points: 
  • March 22, 2024) include:
    Acceptable safety profile: No dose limiting toxicity (DLT) reported and no evidence of vascular leak syndrome (VLS).
  • A new lymph node lesion developed during a 8-week MDNA11 treatment break (vacation) was treated with a single course of radiotherapy prior to resumption of MDNA11.
  • A new lymph node lesion developed at week 16 while baseline target and non-target lesions remained stable or decreased.
  • Monotherapy expansion is continuing to enroll patients with metastatic melanoma, non-melanoma skin cancers (cSCC, MCC, and BCC) and MSI-H/dMMR tumors.